Table 4.
Results and analyses of difference ERP components
| Migraineurs | Healthy controls | Statistics | ||||||
|---|---|---|---|---|---|---|---|---|
| Difference ERPs | Males | Females | Males | Females | Group F(1,88) | Gender F(1,88) | Group × Gender F(1,88) | |
| P3dT | Amplitude (μV) | 5.061 ± 2.200 | 3.086 ± 1.668 | 5.698 ± 3.109 | 6.367 ± 3.840 | 20.225*** | 2.245 | 9.215** |
| Latency (ms) | 428.406 ± 34.649 | 417.841 ± 39.290 | 423.594 ± 37.222 | 415.478 ± 36.722 | 0.407 | 2.760 | 0.047 | |
| P3dN | Amplitude (μV) | 5.606 ± 2.007 | 3.787 ± 1.740 | 6.288 ± 2.137 | 6.950 ± 3.440 | 26.334*** | 2.383 | 10.955** |
| Latency (ms) | 387.754 ± 36.008 | 395.580 ± 35.748 | 396.464 ± 32.580 | 384.058 ± 38.505 | 0.056 | 0.148 | 2.890 | |
| P2dN | Amplitude (μV) | 4.529 ± 2.628 | 3.072 ± 2.208 | 4.407 ± 2.283 | 4.922 ± 2.651 | 6.643* | 1.974 | 8.650** |
| Latency (ms) | 165.362 ± 34.496 | 162.971 ± 32.135 | 176.594 ± 35.897 | 170.522 ± 37.271 | 2.867 | 0.582 | 0.110 | |
Data were expressed as mean ± SD
P3dT, P3dN and P2dN represent the P3 target effect (target minus standard), P3 and P2 novel effects (novel minus standard), respectively
*P < 0.05, **P < 0.01, ***P < 0.001 by repeated-measures ANOVA (Bonferroni correction)